Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).

ABSTRACT:

SUBMITTER: Liu XY 

PROVIDER: S-EPMC12831270 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature